4 completed, 3 unknown, 2 active not recruiting, 2 recruiting. 12 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 12 | Completed 4, Unknown 3, Active not recruiting 2, Recruiting 2, Withdrawn 1 |
| Phase 3 | 1 | Completed 1 |
Follow palmidrol: new trials by email Literature Review of palmidrol trials Research Report on palmidrol
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Sleep and Stress Study Lavender Oil, Palmitoylethanolamide (PEA), Oleoylethanolamide - Sleep Disorder (Disorder), Stress | Phase 2 | Recruiting | RDC Clinical Pty Ltd | 240 | 2026-04-07 | 2026-04-23 |
| Levagen+ Efficacy Study on Diabetic Peripheral Neuropathy Levagen+, Placebo - Diabetic Peripheral Neuropathy | Phase 2 | Recruiting | RDC Clinical Pty Ltd | 80 | 2025-07-01 | 2025-07-23 |
| Long-Term PEA Safety Study Palmitoylethanolamide (PEA), Placebo - Healthy, Safety | Phase 2 | Active not recruiting | RDC Clinical Pty Ltd | 200 | 2025-01-22 | 2026-09-09 |
| Palmitoylethanolamide for Chronic Inflammatory Pain Conditions Palmitoylethanolamide 600mg twice a day, placebo - Chronic Pain | Phase 2 | Unknown | Navy Medical Center San Diego | 80 | 2024-08-05 | 2024-08-15 |
| A Trial of the Fatty Acid Amide Hydrolase Inhibitor Palmitoylethanolamide in Bipolar Depression Palmitoylethanolamide (PEA), Placebo, Treatment as Usual (TAU) - Bipolar Depression | Phase 2 | Completed | Rodrigo Machado-Vieira, MD, PhD, MSc | 34 | 2023-05-17 | 2026-08-13 |
| Effect of Palmitoylethanolamide on Reducing Opioid Consumption for Below Knee Fracture Fixation Palmitoylethanolamide, Placebo - Tibial Fractures, Fibula Fracture | Phase 2 | Withdrawn | University of California, Irvine | 2023-05-01 | 2023-05-09 | |
| PEA vs. Placebo for Major Depression Palmitoylethanolamide - Bipolar Depression, Major Depressive Disorder | Phase 2 | Unknown | The Israeli Medical Center for Alzheimer's | 100 | 2022-12-21 | 2023-10-02 |
| PEA for the Relief of Chemotherapy-Induced Peripheral Neuropathy Palmidrol, Placebo Administration, Quality-of-Life Assessment - Chemotherapy-Induced Peripheral Neuropathy, Hematopoietic and Lymphoid Cell Neoplasm | Phase 2 | Active not recruiting | Academic and Community Cancer Research United | 88 | 2022-05-16 | 2025-09-22 |
| The Effectiveness of a Topical Palmitoylethanolamide (PEA) Formulation (Levagen+) for Reducing Symptoms of Eczema 1.5% Palmitoylethanolamide (PEA) sold as Levagen+, Placebo Comparator - Eczema, Atopic | Phase 2 / Phase 3 | Completed | RDC Clinical Pty Ltd | 72 | 2021-11-29 | 2023-11-18 |
| A Study to Examine the Efficacy of a Therapeutic THX-110 for Tourette Syndrome THX-110 (dronabinol plus PEA), Placebo - Tourette Syndrome | Phase 2 | Unknown | Neurothera Labs Inc. | 60 | 2018-08-01 | 2018-08-29 |
| Efficacy of a Therapeutic Combination of Dronabinol and PEA for Tourette Syndrome Dronabinol and Palmitoylethanolamide - Tourette Syndrome | Phase 2 | Completed | Yale University | 17 | 2017-02-01 | 2020-02-24 |
| Effects of Palmitoylethanolamide on Inner Retinal Function in Glaucoma Patients by Pattern Electroretinogram palmitoylethanolamide (PEA) 600 mg - Glaucoma | Phase 2 | Completed | Fondazione IRCCS Policlinico San Matteo di Pavia | 40 | 2015-03-09 | 2019-09-12 |
Bipolar Disorder (2) · Tourette Syndrome (2) · Anxiety Disorders (1) · Chronic Pain (1) · Depressive Disorder, Major (1) · Dermatitis, Atopic (1) · Fibula Fractures (1) · Glaucoma (1) · Hematologic Neoplasms (1) · Inflammation (1) · Knee Fractures (1) · Pain, Postoperative (1) · Sleep Wake Disorders (1) · Tibial Fractures (1) · Tics (1)
RDC Clinical Pty Ltd (4) · Academic and Community Cancer Research United (1) · Fondazione IRCCS Policlinico San Matteo di Pavia (1) · Navy Medical Center San Diego (1) · Neurothera Labs Inc. (1) · Rodrigo Machado-Vieira, MD, PhD, MSc (1) · The Israeli Medical Center for Alzheimer's (1) · University of California, Irvine (1) · Yale University (1)
United States (5) · Australia (4) · Germany (1) · Moldova (1)
Ariana Nelson, MD (1) · David Briskey, PhD (1) · Mellar P Davis (1) · Michael H. Bloch, MD, MS (1) · RV Venkatesh (1) · Ramasamy Venkatesh (1) · Rodrigo Machado-Vieira, M.D, Ph.D., M.Sc (1)
P30CA015083 (1)